Friday, 23 October 2026

Health

European Commission approves AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with BRCA1/2-mutated metastatic hormone-sensitive prostate cancer (mHSPC)

The European Commission has approved AKEEGA® (niraparib and abiraterone acetate) for patients with BRCA1/2-mutated metastatic hormone-sensitive prostate cancer, following Phase 3 data showing a significant delay in disease progression and an early survival benefit.

By Chantal Thurlby-Alexander Updated 4 min read
CAR T-cell therapies

Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall survival versus standard of care.[1]

Results demonstrate a delay in disease progression and an early trend toward improved overall survival with the niraparib and abiraterone acetate regimen versus standard of care in the treatment of mHSPC.[1]

For verified healthcare professionals

Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.

Register for free Log in

Related stories

Join the conversation

Comments are open to registered members. Log in or register to share your thoughts on this article.

Log in to comment Register for free